Brock Pluimer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brock Pluimer has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Chan
School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA
1 shared publication - Anjali K. Nath
Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
1 shared publication - Anshu Agrawal
Division of Basic and Clinical Immunology, Department of Medicine, University of California Irvine, Irvine, USA
1 shared publication Anson Kairys
1 shared publication- Anthony Gianni Vaccaro
Winston Center for Brain Development and Technology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
1 shared publication Antonio Damasio
Brain and Creativity Institute, University of Southern California, Los Angeles, CA, USA
1 shared publication
Latest Publications
- Open Access
- 2 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1692-1704
Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial
Background: We conducted a randomized, double-blinded pilot trial to compare the impact of two electroacupuncture (EA) regimens on co-occurring neuropsychiatric symptoms among breast cancer survivors (BCS). Methods: BCS who self-reported cognitive impairment, fatigue, insomnia, or psychological distress were randomized (1:1) to receive ten weekly EA to target either neuropsychiatric-specific (nEA) or non-neuropsychiatric-specific (sEA) acupoints. Primary endpoints were the within-group pre-post effect sizes (Glass’s Δ) in symptom severities, adjusted for multiple comparisons (p-adjusted). Outcomes were assessed using neurocognitive tests (CANTAB®), PROs (FACT-Cog, MFSI-SF, EORTC QLQ-C30), plasma biomarkers, and neuroimaging. Responders were defined by reliable change index (for objective cognition) or MCID (for PROs). Results: Thirty-five were recruited, with 30 (86%) completing all sessions. The mean (±SD) age was 58.2 (±12.2) years, and 86% reported co-occurring symptoms. Following treatment, the nEA group demonstrated significant improvements in attention (T3: Δ = 0.562, T4: Δ = 0.708, both p-adjusted < 0.05) and distress (T3: Δ = 0.764, T4: Δ = 0.711, both p-adjusted < 0.05). More responders were observed after nEA treatment for objective cognition (42.9% vs 12.5%) and distress (50% vs 37.5%). nEA-treated participants showed increased gray matter volume compared to sEA (p = 0.033), which positively correlated with better attention function (r = 0.69, p = 0.020). nEA-related improvements in memory and response speed were associated with reduced connectivity in the Default Mode Network (DMN–SFG, r=-0.93, p < 0.01) and increased connectivity in the Dorsal Attention Network (DAN–SMG, r = 0.86, p < 0.001), respectively. All adverse events were grade 2 or lower. Conclusions: EA targeting neuropsychiatric-specific acupoints suggests improvements in cognition and distress symptoms in BCS, warranting validation in larger, multicenter trials. Clinicaltrials.gov: NCT05283577.
- 2 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (9) , 1692-1704
Open AccessElectroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial
Background: We conducted a randomized, double-blinded pilot trial to compare the impact of two electroacupuncture (EA) regimens on co-occurring neuropsychiatric symptoms among breast cancer survivors (BCS). Methods: BCS who self-reported cognitive impairment, fatigue, insomnia, or psychological distress were randomized (1:1) to receive ten weekly EA to target either neuropsychiatric-specific (nEA) or non-neuropsychiatric-specific (sEA) acupoints. Primary endpoints were the within-group pre-post effect sizes (Glass’s Δ) in symptom severities, adjusted for multiple comparisons (p-adjusted). Outcomes were assessed using neurocognitive tests (CANTAB®), PROs (FACT-Cog, MFSI-SF, EORTC QLQ-C30), plasma biomarkers, and neuroimaging. Responders were defined by reliable change index (for objective cognition) or MCID (for PROs). Results: Thirty-five were recruited, with 30 (86%) completing all sessions. The mean (±SD) age was 58.2 (±12.2) years, and 86% reported co-occurring symptoms. Following treatment, the nEA group demonstrated significant improvements in attention (T3: Δ = 0.562, T4: Δ = 0.708, both p-adjusted < 0.05) and distress (T3: Δ = 0.764, T4: Δ = 0.711, both p-adjusted < 0.05). More responders were observed after nEA treatment for objective cognition (42.9% vs 12.5%) and distress (50% vs 37.5%). nEA-treated participants showed increased gray matter volume compared to sEA (p = 0.033), which positively correlated with better attention function (r = 0.69, p = 0.020). nEA-related improvements in memory and response speed were associated with reduced connectivity in the Default Mode Network (DMN–SFG, r=-0.93, p < 0.01) and increased connectivity in the Dorsal Attention Network (DAN–SMG, r = 0.86, p < 0.001), respectively. All adverse events were grade 2 or lower. Conclusions: EA targeting neuropsychiatric-specific acupoints suggests improvements in cognition and distress symptoms in BCS, warranting validation in larger, multicenter trials. Clinicaltrials.gov: NCT05283577.
- Open Access
- 24 January 2026
- Published by Elsevier in Neuroscience Informatics
- Vol. 6 (1)
A proof-of-concept study on the use of large language models for assessing research methodology in neuroimaging
- 24 January 2026
- Published by Elsevier in Neuroscience Informatics
- Vol. 6 (1)
Open AccessA proof-of-concept study on the use of large language models for assessing research methodology in neuroimaging
- 12 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Robotics
- Vol. 8 (80) , eabq3658
Preventing antisocial robots: A pathway to artificial empathy
Given the accelerating powers of artificial intelligence (AI), we must equip artificial agents and robots with empathy to prevent harmful and irreversible decisions. Current approaches to artificial empathy focus on its cognitive or performative processes, overlooking affect, and thus promote sociopathic behaviors. Artificially vulnerable, fully empathic AI is necessary to prevent sociopathic robots and protect human welfare.
- 12 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Robotics
- Vol. 8 (80) , eabq3658
Preventing antisocial robots: A pathway to artificial empathy
Given the accelerating powers of artificial intelligence (AI), we must equip artificial agents and robots with empathy to prevent harmful and irreversible decisions. Current approaches to artificial empathy focus on its cognitive or performative processes, overlooking affect, and thus promote sociopathic behaviors. Artificially vulnerable, fully empathic AI is necessary to prevent sociopathic robots and protect human welfare.
- Open Access
- 23 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (47) , eabm7069
Top2a promotes the development of social behavior via PRC2 and H3K27me3
Little is understood about the embryonic development of sociality. We screened 1120 known drugs and found that embryonic inhibition of topoisomerase IIα (Top2a) resulted in lasting social deficits in zebrafish. In mice, prenatal Top2 inhibition caused defects in social interaction and communication, which are behaviors that relate to core symptoms of autism. Mutation of Top2a in zebrafish caused down-regulation of a set of genes highly enriched for genes associated with autism in humans. Both the Top2a-regulated and autism-associated gene sets have binding sites for polycomb repressive complex 2 (PRC2), a regulatory complex responsible for H3K27 trimethylation (H3K27me3). Moreover, both gene sets are highly enriched for H3K27me3. Inhibition of the PRC2 component Ezh2 rescued social deficits caused by Top2 inhibition. Therefore, Top2a is a key component of an evolutionarily conserved pathway that promotes the development of social behavior through PRC2 and H3K27me3.
- 23 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (47) , eabm7069
Open AccessTop2a promotes the development of social behavior via PRC2 and H3K27me3
Little is understood about the embryonic development of sociality. We screened 1120 known drugs and found that embryonic inhibition of topoisomerase IIα (Top2a) resulted in lasting social deficits in zebrafish. In mice, prenatal Top2 inhibition caused defects in social interaction and communication, which are behaviors that relate to core symptoms of autism. Mutation of Top2a in zebrafish caused down-regulation of a set of genes highly enriched for genes associated with autism in humans. Both the Top2a-regulated and autism-associated gene sets have binding sites for polycomb repressive complex 2 (PRC2), a regulatory complex responsible for H3K27 trimethylation (H3K27me3). Moreover, both gene sets are highly enriched for H3K27me3. Inhibition of the PRC2 component Ezh2 rescued social deficits caused by Top2 inhibition. Therefore, Top2a is a key component of an evolutionarily conserved pathway that promotes the development of social behavior through PRC2 and H3K27me3.